LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The global competent cells market will grow at a CAGR of 10% during the forecast period to reach USD 2,318.6 million by 2023, primarily driven by “growing demand for recombinant proteins and molecular cloned products, advancement in molecular cloning research with emergence of new technologies, various government initiatives, and growing funding for life science research,” Meticulous Research™ noted in a press release today.

Request Sample Report: https://www.meticulousresearch.com/request-sample-report/?cp_id=3723

The report notes that cloned competent cells held the largest share, owing to “their rising adoption in research with increasing feasibility of genetic therapy, growing need for rapid diagnosis & treatment, favorable government support for cloning based research in various countries, and rising availability of sophisticated instruments and technology.”

Geographically, North America held the largest share in this market, due to ”its well-established healthcare system, higher acceptance of advanced technologies, raising non-communicable diseases & related rise in pharmaceutical research & development, increase in cloning based research, favorable reimbursement scenario, and presence of key players in this market.”

The key players in this market are Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Merck & Company, Inc., Illumina, Inc., Promega Corporation, New England Biolabs, OriGene Technologies, Inc., Zymo Research Corporation, Scarab Genomics, LLC, Meridian Bioscience, Inc., Delphi Genetics S.A., Qiagen N.V., Cell Applications, Inc., GenScript Biotech Corporation, and Takara Holdings Inc.

Browse in-depth report on: https://www.meticulousresearch.com/product/competent-cells-market-forecast-2023/

Report Scope:

Type:

• Cloned Competent Cells
• Agrobacterium tumefaciens Competent Cells
• Expression Competent Cells

Treatment:

• Chemically Competent Cells
• Electrocompetent Cells

Application:

• Cloning
  • Subcloning & Routine Cloning
  • Toxic/Unstable DNA Cloning
  • High-Throughput Cloning
  • Phage Display Library production
• Protein Expression
• Others
  • Single Stranded DNA Preparation
  • Mutagenesis Study
  • Large Plasmid Transformation
  • Lentiviral Vector Production

End User:

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations

Geographic scope:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Turkey
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

             
Enquire before buying: https://www.meticulousresearch.com/enquire-before-buying/?cp_id=3723

Contact Info:

Viren Shrivastava

Email: viren@meticulousresearch.com

Direct Lines: +1-646-781-8004 (North America)

+44-203-868-8738 (Europe)

+91 744-7780008 (Asia-Pacific)